Vitamin D insufficiency has been suggested as a dementia risk factor.
Objective:
In this cross-sectional, explorative study we investigated whether levels of vitamin D in cerebrospinal fluid (CSF) are lower in patients with positive biomarkers of Alzheimer’s disease (AD) compared to cognitively healthy controls and whether polymorphisms of the vitamin D receptor (VDR) gene, FokI, BsmI, ApaI, and TaqI, are associated with levels of vitamin D in CSF and cognition.
Methods:
We included 100 patients≥65 years assessed for cognitive impairment and 76 cognitively healthy controls. Levels of 25-hydroxyvitamin D (25(OH)D) in both serum and CSF, and VDR polymorphisms were analyzed.
Results:
The mean level of 25(OH)D in serum was 78.6 (SD 28.9) nmol/l. While serum levels of 25(OH)D were not significantly different between the groups, CSF levels of 25(OH)D were significantly lower in patients with positive AD core biomarkers (p = 0.001) compared to patients without such biomarkers. Individuals with the BsmI major homozygote genotype had significantly lower results on a 10-word delayed recall test (p = 0.044) and verbal fluency test (p = 0.013), and individuals with the TaqI major homozygote genotype had significantly lower results on a verbal fluency test (p = 0.030) compared to individuals with the corresponding minor homozygote genotype.
Conclusion:
Patients with positive AD core biomarkers have low CSF levels of 25(OH)D, despite sufficient serum levels. CSF levels of 25(OH)D do not seem to be affected by any of the four VDR gene polymorphisms. TaqI and BsmI major homozygote genotypes might be at increased risk for development of cognitive decline.
PradoEL, DeweyKG (2014) Nutrition and brain development in early life. Nutr Rev72, 267–284.
2.
SultanS, TaimuriU, BasnanSA, Ai-OrabiWK, AwadallahA, AlmowaldF, HazaziA (2020) Low vitamin D and its association with cognitive impairment and dementia. J Aging Res2020, 6097820.
3.
Zugic SoaresJ, PettersenR, Saltyte BenthJ, KnapskogAB, SelbaekG, BogdanovicN (2019) Higher vitamin D levels are associated with better attentional functions: Data from the NorCog Register. J Nutr Health Aging23, 725–731.
4.
FrameLA, FischerJP, GellerG, CheskinLJ (2018) Use of placebo in supplementation studies-vitamin D research illustrates an ethical quandary. Nutrients10, 347.
5.
RamagopalanSV, HegerA, BerlangaAJ, MaugeriNJ, LincolnMR, BurrellA, HandunnetthiL, HandelAE, DisantoG, OrtonSM, WatsonCT, MorahanJM, GiovannoniG, PontingCP, EbersGC, KnightJC (2010) A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Res20, 1352–1360.
6.
BeydounMA, TajuddinSM, DoreGA, CanasJA, BeydounHA, EvansMK, ZondermanAB (2017) Vitamin D receptor and Megalin gene polymorphisms are associated with longitudinal cognitive change among African-American urban adults. J Nutr147, 1048–1062.
7.
GarcionE, Wion-BarbotN, Montero-MeneiCN, BergerF, WionD (2002) New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab13, 100–105.
8.
ValdivielsoJM, FernandezE (2006) Vitamin D receptor polymorphisms and diseases. Clin Chim Acta371, 1–12.
9.
MendelCM (1989) The free hormone hypothesis: A physiologically based mathematical model. Endocr Rev10, 232–274.
10.
ChunRF, PeercyBE, OrwollES, NielsonCM, AdamsJS, HewisonM (2014) Vitamin D and DBP: The free hormone hypothesis revisited. J Steroid Biochem Mol Biol144 Pt A, 132–137.
11.
BikleDD, GeeE, HalloranB, KowalskiMA, RyzenE, HaddadJG (1986) Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab63, 954–959.
12.
BikleDD, SchwartzJ (2019) Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. Front Endocrinol (Lausanne)10, 317.
13.
BikleD, BouillonR, ThadhaniR, SchoenmakersI (2017) Vitamin D metabolites in captivity? Should we measure free or total 25(OH)D to assess vitamin D status?J Steroid Biochem Mol Biol173, 105–116.
14.
VermeulenA, VerdonckL, KaufmanJM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab84, 3666–3672.
15.
FraserWD, TangJCY, DuttonJJ, SchoenmakersI (2020) Vitamin D measurement, the debates continue, new analytes have emerged, developments have variable outcomes. Calcif Tissue Int106, 3–13.
StrandH, GarabetL, BjelkeB, SithiravelC, HardangIM, MoeMK (2021) beta-Amyloid in cerebrospinal fluid: How to keep it floating (not sticking) by standardization of preanalytic processes and collection tubes. J Appl Lab Med6, 1155–1164.
19.
KochW, EhrenhaftA, GriesserK, PfeuferA, MullerJ, SchomigA, KastratiA (2002) TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin Chem Lab Med40, 1123–1131.
20.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr., KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
21.
WinbladB, PalmerK, KivipeltoM, JelicV, FratiglioniL, WahlundLO, NordbergA, BackmanL, AlbertM, AlmkvistO, AraiH, BasunH, BlennowK, de LeonM, DeCarliC, ErkinjunttiT, GiacobiniE, GraffC, HardyJ, JackC, JormA, RitchieK, van DuijnC, VisserP, PetersenRC (2004) Mild cognitive impairment–beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med256, 240–246.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
StraussE SE, SpreenO. (2006) A Compendium of Neuropschological Tests, Oxford University Press, New York.
26.
MorrisJC, HeymanA, MohsRC, HughesJP, van BelleG, FillenbaumG, MellitsED, ClarkC (1989) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology39, 1159–1165.
27.
Malek-AhmadiM, SmallBJ, RajA (2011) The diagnostic value of controlled oral word association test-FAS and category fluency in single-domain amnestic mild cognitive impairment. Dement Geriatr Cogn Disord32, 235–240.
28.
HolmoyT, MoenSM, GundersenTA, HolickMF, FainardiE, CastellazziM, CasettaI (2009) 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult Scler15, 1280–1285.
29.
BalabanovaS, RichterHP, AntoniadisG, HomokiJ, KremmerN, HanleJ, TellerWM (1984) 25-Hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid. Klin Wochenschr62, 1086–1090.
30.
ZelzerS, MeinitzerA, HerrmannM, GoesslerW, EnkoD (2021) A novel method for the determination of vitamin D metabolites assessed at the blood-cerebrospinal fluid barrier. Biomolecules11, 1288.
31.
MoghtaderiA, TamadonGH, HaghighiF (2013) 25-hydro-xyvitamin D3 concentration in serum and cerebrospinal fluid of patients with remitting-relapse multiple sclerosis. Prague Med Rep114, 162–171.
32.
JohanssonP, AlmqvistEG, JohanssonJO, MattssonN, AndreassonU, HanssonO, WallinA, BlennowK, ZetterbergH, SvenssonJ (2013) Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholine-sterase activity are reduced in patients with Alzheimer’s disease. PLoS One8, e81989.
33.
LeeDH, KimJH, JungMH, ChoMC (2019) Total 25-hydroxy vitamin D level in cerebrospinal fluid correlates with serum total, bioavailable, and free 25-hydroxy vitamin D levels in Korean population. PLoS One14, e0213389.
34.
LeeDH, KangH, KimJH, JungMH, ChoMC (2019) Cerebrospinal fluid vitamin D-binding protein as a new biomarker for the diagnosis of meningitis. Neurol Sci40, 1597–1605.
35.
DursunE, Gezen-AkD (2019) Vitamin D basis of Alzhei-mer’s disease: From genetics to biomarkers. Hormones (Athens)18, 7–15.
36.
AtkinsonSA (2011) [The new dietary reference intakes from the Institute of Medicine for calcium and vitamin D]. Perspect Infirm8, 5.
37.
HsuSA, SoldoJ, GuptaM (2013) Evaluation of two automated immunoassays for 25-OH vitamin D: Comparison against LC-MS/MS. J Steroid Biochem Mol Biol136, 139–145.
38.
HolickMF, BinkleyNC, Bischoff-FerrariHA, GordonCM, HanleyDA, HeaneyRP, MuradMH, WeaverCM, EndocrineSociety (2011) Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab96, 1911–1930.
39.
DivanoglouN, KomninouD, SteaEA, ArgiriouA, PapatzikasG, TsakalofA, Pazaitou-PanayiotouK, GeorgakisMK, PetridouE (2021) Association of vitamin D receptor gene polymorphisms with serum vitamin D levels in a Greek rural population (Velestino Study). Lifestyle Genom14, 81–90.
40.
MoosaviE, RafieiA, YazdaniY, EslamiM, SaeediM (2021) Association of serum levels and receptor genes BsmI, TaqI and FokI polymorphisms of vitamin D with the severity of multiple sclerosis. J Clin Neurosci84, 75–81.
41.
SmoldersJ, DamoiseauxJ, MenheereP, TervaertJW, HuppertsR (2009) Association study on two vitamin D receptor gene polymorphisms and vitamin D metabolites in multiple sclerosis. Ann N Y Acad Sci1173, 515–520.
42.
RasheedH, HegazyRA, GawdatHI, MehaneyDA, KamelMM, FawzyMM, NoohMM, DarwishHA (2016) Serum vitamin D and vitamin D receptor gene polymorphism in mycosis fungoides patients: A case control study. PLoS One11, e0158014.
43.
LiuN, ZhangT, MaL, WeiW, LiZ, JiangX, SunJ, PeiH, LiH (2021) Vitamin D receptor gene polymorphisms and risk of Alzheimer disease and mild cognitive impairment: A systematic review and meta-analysis. Adv Nutr12, 2255–2264.
44.
Ruiz-BallesterosAI, Meza-MezaMR, Vizmanos-LamotteB, Parra-RojasI, de la Cruz-MossoU (2020) Association of vitamin D metabolism gene polymorphisms with autoimmunity: Evidence in population genetic studies. Int J Mol Sci21, 9626.
45.
ArevaloN, CastilloD, RogersN, DelgadoC, FaríasG, BehrensMI, SanMartínCD (2020) Apa I, Taq I and Fok I VDR polymorphisms: Functional effect on mRNA levels of amyloid beta transporters LRP1 and P-gp in lymphocytes of mild cognitive impairment patients. Alzheimer Dement16, e045564.
46.
ArevaloNB, Castillo-GodoyDP, Espinoza-FuenzalidaI, RogersNK, FariasG, DelgadoC, HenriquezM, HerreraL, BehrensMI, SanMartinCD (2021) Association of vitamin D receptor polymorphisms with amyloid-beta transporters expression and risk of mild cognitive impairment in a Chilean cohort. J Alzheimers Dis82, S283–S297.
47.
BeydounMA, DingEL, BeydounHA, TanakaT, FerrucciL, ZondermanAB (2012) Vitamin D receptor and megalin gene polymorphisms and their associations with longitudinal cognitive change in US adults. Am J Clin Nutr95, 163–178.
48.
KuningasM, MooijaartSP, JollesJ, SlagboomPE, WestendorpRG, van HeemstD (2009) VDR gene variants associate with cognitive function and depressive symptoms in old age. Neurobiol Aging30, 466–473.
49.
EylesDW, SmithS, KinobeR, HewisonM, McGrathJJ (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat29, 21–30.
50.
BahramiA, KhayyatzadehSS, JaberiN, TayefiM, MohammadiF, FernsGA, SadeghniaHR, Ghayour-MobarhanM (2019) Common polymorphisms in genes related to vitamin D metabolism affect the response of cognitive abilities to vitamin D supplementation. J Mol Neurosci69, 150–156.
51.
Gezen-AkD, DursunE, ErtanT, HanagasiH, GurvitH, EmreM, EkerE, OzturkM, EnginF, YilmazerS (2007) Association between vitamin D receptor gene polymorphism and Alzheimer’s disease. Tohoku J Exp Med212, 275–282.
52.
Khorram KhorshidHR, GozalpourE, SaliminejadK, KarimlooM, OhadiM, KamaliK (2013) Vitamin D receptor (VDR) polymorphisms and late-onset Alzheimer’s disease: An association study. Iran J Public Health42, 1253–1258.
53.
LehmannDJ, RefsumH, WardenDR, MedwayC, WilcockGK, SmithAD (2011) The vitamin D receptor gene is associated with Alzheimer’s disease. Neurosci Lett504, 79–82.
54.
JordeR, MathiesenEB, RogneS, WilsgaardT, KjaergaardM, GrimnesG, SchirmerH (2015) Vitamin D and cognitive function: The Tromso Study. J Neurol Sci355, 155–161.
55.
HuebbeP, NebelA, SiegertS, MoehringJ, Boesch-SaadatmandiC, MostE, PallaufJ, EgertS, MullerMJ, SchreiberS, NothlingsU, RimbachG (2011) APOE epsilon4 is associated with higher vitamin D levels in targeted replacement mice and humans. FASEB J25, 3262–3270.
56.
SoaresJZ, PettersenR, BenthJS, PerssonK, StrobelC, SelbaekG, BogdanovicN (2021) Vitamin D levels, APOE allele, and MRI volumetry assessed by NeuroQuant in Norwegian adults with cognitive symptoms. J Alzheimers Dis79, 311–321.
57.
DursunE, AlayliogluM, BilgicB, HanagasiH, LohmannE, AtasoyIL, CandasE, ArazOS, OnalB, GurvitH, YilmazerS, Gezen-AkD (2016) Vitamin D deficiency might pose a greater risk for ApoEvarepsilon4 non-carrier Alzheimer’s disease patients. Neurol Sci37, 1633–1643.
